The role of pemetrexed as maintenance treatment in advanced NSCLC: A Phase III randomized trial

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 2, 2010, Pages 321-324

  Gridelli, Cesare ^a   Di Maio, Massimo ^b  

^a S G MOSCATI HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Maintenance treatment; Non small cell lung cancer; Pemetrexed

Indexed keywords

PEMETREXED; PLACEBO;

ADVANCED CANCER; CANCER GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NOTE; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL;

AGE FACTORS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PLACEBOS; RISK FACTORS; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 76749169766     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903485672     Document Type: Note

References (10)

1. Ciuleanu T, Brodowicz T, Zielinski C, et al.. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, Phase III study. Lancet 2009: published online 20 September 2009, doi: 10.1016/S0140-6736(09)61497-5
2. Hanna N, Shepherd FA, Fossella FV, et al.. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597
3. Scagliotti GV, Parikh P, von Pawel J, et al.. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551
4. Scagliotti G, Hanna N, Fossella F, et al.. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009;14:253-263
5. Pfister DG, Johnson DH, Azzoli CG, et al.. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353
6. National Comprehensive Cancer Network - Clinical Practice Guidelines in Oncology. Non-small-cell lung cancer. Version 2.2009. Available from: www.nccn.org [Last accessed 5 November 2009]
7. Socinski MA, Crowell R, Hensing TE, et al.. American College of Chest Physicians. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines. 2nd edition. Chest 2007;132(3 Suppl):277S-89S
8. Fidias PM, Dakhil SR, Lyss AP, et al.. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-598
9. Socinski MA. Re-evaluating duration of therapy in advanced non-small-cell lung cancer: is it really duration or is it more about timing and exposure? J Clin Oncol 2009;27:3268-3270
10. Stinchcombe TE, West HL. Maintenance therapy in non-small-cell lung cancer. Lancet 2009: published online 20 September 2009, doi: 10.1016/S0140-6736(09)61598-1